• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Veracyte (VCYT) Could Be 22% Undervalued As Decipher Data Strengthens Its Growth Case

    Simply Wall St·10/13/2026 16:23:27
    Listen to the news

    Why the new Decipher data matters for Veracyte investors

    Veracyte (VCYT) is drawing fresh attention after new Decipher Prostate Genomic Classifier findings from a large phase III trial were selected for presentation at the 2026 ASTRO Annual Meeting.

    The ancillary analysis from the NRG/RTOG 0815 study suggests Decipher scores helped identify which men with intermediate risk prostate cancer gained more from adding short term androgen deprivation therapy to dose escalated radiation, and which saw limited benefit.

    Against that clinical backdrop, Veracyte’s recent trading has been choppy, with the share price falling 7.7% over the past week but still showing a 7.7% gain over 30 days and a 3.9% year-to-date share price return. The 1-year total shareholder return of 29.1% and 3-year total shareholder return of about 2.1x suggest that longer-term holders have experienced far stronger gains than short-term traders.

    Scan beyond Veracyte to find other precision oncology players that could be building similar momentum with genomics driven products inside our curated 33 healthcare AI stocks

    After a sharp 7.7% pullback in a week, yet a 29.1% 1 year total return, Veracyte now forces a timing call. Is the current price fair value, or is patience rewarded here?

    Most Popular Narrative: 22% Undervalued

    Veracyte’s most followed valuation narrative pegs fair value at $56.55, compared with the recent $44.02 close, so the gap rests firmly on expectations around cash generation and pipeline execution.

    Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration. Continued market penetration and share gains for Decipher Prostate, including expansion into metastatic and high-risk segments (now covering the entire prostate cancer spectrum), are fueling outsized growth; robust clinical evidence and guideline inclusions are likely to drive further physician adoption and payer coverage, bolstering both revenues and earnings visibility.

    See why 13 investors see Veracyte as 22% undervalued.

    Result: Fair Value of $56.55 (UNDERVALUED)

    Still, the Veracyte narrative can crack if payer coverage disappoints on newer tests or if larger diagnostics rivals use AI and digital pathology to squeeze its share.

    Find out about the key risks to this Veracyte narrative.

    Next Steps

    Mixed signals around Veracyte can either paralyze you or prompt a closer look at the full picture of risk and upside. To stress test your own thesis against both sides of the argument, start with the 4 key rewards and 1 important warning sign.

    Looking for more Veracyte sized investment ideas?

    If Veracyte has sharpened your appetite for opportunities, do not stop here. Use Simply Wall Street screeners to uncover focused ideas tailored to your next move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.